A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Epirubicin is a common chemotherapy medication used in the treatment of breast cancer.
However, chemotherapy dosing is calculated based on people's height and weight, which may not
be the most accurate way. The purpose of this study is to see if epirubicin dosing based on
people's genetic profiles is better than the usual methods.